These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24990656)

  • 21. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Alatawi YM; Hansen RA
    Expert Opin Drug Saf; 2017 Jul; 16(7):761-767. PubMed ID: 28447485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can social media data lead to earlier detection of drug-related adverse events?
    Duh MS; Cremieux P; Audenrode MV; Vekeman F; Karner P; Zhang H; Greenberg P
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1425-1433. PubMed ID: 27601271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
    Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
    Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification.
    Osokogu OU; Dodd C; Pacurariu A; Kaguelidou F; Weibel D; Sturkenboom MC
    Drug Saf; 2016 Sep; 39(9):873-81. PubMed ID: 27255487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.
    Sorbello A; Jones SC; Carter W; Struble K; Boucher R; Truffa M; Birnkrant D; Gada N; Camilli S; Chan I; Dallas S; Scales T; Kosko R; Thompson E; Goodman J; Francis H; Dal Pan G
    Clin Infect Dis; 2012 Jul; 55(1):1-7. PubMed ID: 22491501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
    Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
    J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.
    Alsuhibani A; Alrasheed M; Gari M; Hincapie AL; Guo JJ
    Int J Clin Pharm; 2022 Feb; 44(1):172-179. PubMed ID: 34564826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.
    Moore TJ; Cohen MR; Furberg CD
    Arch Intern Med; 2007 Sep; 167(16):1752-9. PubMed ID: 17846394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reported adverse drug events in infants and children under 2 years of age.
    Moore TJ; Weiss SR; Kaplan S; Blaisdell CJ
    Pediatrics; 2002 Nov; 110(5):e53. PubMed ID: 12415059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.